CTOs on the Move

AavantiBio

www.aavantibio.com

 
AavantiBio is a pre-clinical biopharmaceutical company committed to developing and commercializing novel gene transfer and gene editing therapies for the treatment of rare and ultra-rare genetic diseases. The company is rapidly building a diverse portfolio of gene transfer and gene editing therapies to target debilitating genetic diseases for which the unmet medical need is high for which there are typically no approved therapies treating the underlying disease. AavantiBio is headquartered in Cambridge, MA with additional locations in Gainesville, FL. We are looking for exceptional individuals who share our passion for developing novel therapies to treat rare diseases and advancing the ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.aavantibio.com
  • 245 First Street Riverview II, 18th Floor
    Cambridge, MA USA 02142
  • Phone: n/a

Executives

Name Title Contact Details
Paul Herzich
 Chief Technology Officer Profile

Similar Companies

BIA Separations

BIA Separations is a Wilmington, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bioreclamation

Bioreclamation is a Westbury, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Teknova

Teknova offers custom molecular biology media such as buffers and reagents, pre-poured agar plates, dry culture media, liquid culture media, and media supplements.

NewLeaf Symbiotics

NewLeaf Symbiotics® is at the forefront of sustainable agriculture technology, with a singular focus on the identification, development and commercialization of the beneficial microbes called pink pigmented facultative methylotrophs (M-trophs). This new class of agricultural microbes is helping transition agricultural products and production to deliver better quality crops, with less impact on the environment — a win-win for growers and those of us who depend on their success.

Mesoblast

Mesoblast is a world leader in developing innovative cellular medicines. We have established what we believe is the industry`s most clinically advanced and diverse portfolio of cell-based products with five programs, two of which are partnered, in active Phase 3 clinical studies or Phase 3-ready, and four programs in Phase 2. All our clinical programs target significant, under-served therapeutic areas including cardiac diseases, spine orthopedic disorders, oncology and hematology diseases, and immune-mediated and inflammatory conditions.